Baker Bros. Advisors Reduces $52K in Opthea Limited ($OPTEY)
Key Points
- Baker Bros. Advisors changed its Opthea Limited ($OPTEY) stake by 100.0% last quarter, cutting to 0 shares.
- $OPTEY last traded around $0.03.
Baker Bros. Advisors reduced its position in Opthea Limited ($OPTEY), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of Opthea Limited after selling 2,087,320 shares during the quarter.
Opthea Limited ($OPTEY) Stock
Opthea Limited Earnings
About Opthea Limited
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.